Company news

Share this article:
AstraZeneca posted a third quarter sales increase of 3%, to 7.8 billion, according to a company report released today. Emerging markets contributed $1.1 billion – an 18% growth – to the bottom line. In China specifically, the company saw a 35% increase in sales. Crestor profited from its atherosclerosis indication, and US sales of the drug increased by 23%, marking the only branded statin to gain market share in the US this year, according to a company statement. “AstraZeneca has delivered a robust set of results that deliver on our performance commitments despite an increasingly challenging environment for the pharmaceutical sector and business in general,” said David Brennan, CEO, in the report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.